fbpx
22.8 C
Mexico City
sábado, enero 18, 2025

Tami Pingree

spot_img

«LEQEMBI» (Lecanemab) aprobado para el tratamiento de la enfermedad de Alzheimer temprano en México

TOKYO and CAMBRIDGE, Mass., Dec 5, 2024 - (JCN Newswire) -  Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early Alzheimer’s disease (AD)*. LEQEMBI selectively binds to soluble

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img